韩国青少年和年轻成人急性淋巴细胞白血病的治疗模式与结局
该研究利用韩国国家数据,分析青少年和年轻成人急性淋巴细胞白血病(ALL)患者中治疗方案与结局的关系。多因素分析显示,较年轻年龄、L-天冬酰胺酶治疗和放疗与更优OS相关。
要点
- 儿童启发方案(含L-天冬酰胺酶)在AYA ALL中5年OS优于成人方案。
- 年轻年龄、L-天冬酰胺酶治疗和放疗与更优OS独立相关。
- 治疗方案选择对AYA ALL的治疗效果至关重要。
核心结论
- 在AYA ALL患者中,采用含L-天冬酰胺酶的儿童启发方案与更优的OS相关。
研究设计与样本
- 基于韩国国家数据的回顾性研究,纳入青少年和年轻成人ALL患者。
主要发现
- 该OS优势在各年龄亚组中均得以维持。
- 多因素分析显示,较年轻年龄、L-天冬酰胺酶治疗和放疗与更优OS相关。
临床怎么用
- 对于AYA ALL患者,可优先考虑含L-天冬酰胺酶的儿童启发方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study used Korean national data to investigate the relationship between treatment patterns and outcomes in Korean adolescent and young-adult (AYA) acute lymphoblastic leukaemia (ALL) patients. Chemotherapy incorporating L-asparaginase was considered paediatric-inspired (PI), as opposed to adult protocols. In total, 65·3% of patients received PI therapy. Five-year overall survival (OS) of PI-treated patients outperformed adult protocols (63·1% vs. 40·4%; P < 0·0001); this trend was maintained within various age subgroups. Younger age, L-asparaginase therapy, and radiotherapy corresponded with superior OS by multivariable analysis. OS tends to improve with PI protocols that include L-asparaginase in AYA ALL, suggesting that therapy protocol is critical in the treatment performance of this group.
引用
- Kim YA, Ju HY, Park HJ, et al. Outcomes of acute lymphoblastic leukaemia in adolescent and young adult Korean patients. Br J Haematol. 2019. PMID: 31612474. doi:10.1111/bjh.16242
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。